References
- Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135–1145.
- Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–724.
- Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
- Biankin AV, Piantadosi S, Hollingsworth SJ. Patient-centric trials for therapeutic development in precision oncology. Nature. 2015;526:361–370.
- Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11:276–289.
- Friedman AA, Letai A, Fisher DE, et al. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15:747–756.
- Ku C-S, Roukos DH. From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Devices. 2013;10:1–6.
- Mardis ER. DNA sequencing technologies: 2006-2016. Nat Protoc. 2017;12:213–218.
- Kotze MJ, Lückhoff HK, Peeters AV, et al. Genomic medicine and risk prediction across the disease spectrum. Crit Rev Clin Lab Sci. 2015;52:120–137.
- Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495–501.
- The Cancer Genome Atlas. 2017. Available from: https://cancergenome.nih.gov/.
- International Cancer Genome Consortium. 2017. Available from: http://icgc.org/.
- Barabási A-L, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56–68.
- Gao J, Barzel B, Barabási A-L. Universal resilience patterns in complex networks. Nature. 2016;530:307–312.
- Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–5).
- Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47–54.
- Fujimoto A, Furuta M, Totoki Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016;48:500–509.
- Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.
- Roukos DH. Spatiotemporal diversification of intrapatient genomic clones and early drug development strategy concepts realize the roadmap of precision cancer medicine. Drug Discov Today. 2017;22:1148–1164.
- Humphris JL, Patch A-M, Nones K, et al. Hypermutation in pancreatic cancer. Gastroenterology. 2017;152:68–74 e62.
- Illumina. 2017. Available from: https://www.illumina.com/company/news-center/feature-articles/2016in-genomics–year-in-review.html.
- Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of nonsmall-cell lung cancer. N Engl J Med. 2017;376:2109–2121.
- Jansen MP, Martens JW, Helmijr JC, et al. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen. Oncotarget. 2016;7:43412–43418.